ArticleFrontiers in pharmacology2024

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.

Yitian Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.